USA This site is intended for US residents only
  • Important Safety Information
  • ES
  • EN
  • For Healthcare Providers

IMPORTANT SAFETY INFORMATION

RISK OF SERIOUS ALLERGIC REACTIONS

Some patients have experienced serious allergic reactions (including life-threatening anaphylactic reactions) during and up to 24 hours after treatment, regardless of how long they were taking ELAPRASE. Anaphylactic reactions are immediate and include breathing problems, low oxygen levels, low blood pressure, hives and/or swelling of the throat or tongue. If a patient (you or your child) has experienced an anaphylactic reaction, the patient may require an extended period of observation by the patient’s healthcare team. If you or your child has breathing problems, a fever, or a respiratory illness, you or your child may be at risk of life threatening worsening of those conditions due to allergic reactions from ELAPRASE. Your healthcare team should be advised of those conditions before treatment with ELAPRASE because the information may affect the timing of ELAPRASE treatment.

Please see full Prescribing Information and additional Important Safety Information below.

Elaprase
  • About Elaprase
  • Access & Support
  • Stay Updated
  • Important Safety Information
  • Prescribing Information
  • For Healthcare Providers

Site Map

Elaprase.com Sitemap

  • Patients & Families Homepage
  • About Elaprase
    • What is ELAPRASE?
    • How is ELAPRASE dosed?
    • How has ELAPRASE Helped Patients with MPS II?
    • Safety Information
  • Access & Support
    • Patient Support
    • Reimbursement Support
    • OnePath Product Support Team
  • Stay Updated
  • Privacy Policy
  • Terms of Use
  • Cookies Information
  • Unsubscribe
  • Contact Us
  • Healthcare Professionals Homepage
  • About ELAPRASE
    • Elaprase Overview
    • Full Prescribing Information
    • Pivotal Trial Outcome
  • Dosing and Administration
    • Recommended Dose
    • Preparation Instructions
    • Administration Instructions
    • Storage & Stability
  • Access & Support
    • Product Support for Patients
    • Reimbursement
  • Stay Updated
  • Terms of Use
  • Privacy Policy
  • Cookies Information
  • Unsubscribe
  • Contact Us
What is ELAPRASE® (Idursulfase)?

ELAPRASE is a prescription medicine for patients with Hunter syndrome.

ELAPRASE has been shown to improve walking ability in patients 5 yrs and older.

In patients 16 months to 5 yrs old, ELAPRASE did not show improvement in disease-related symptoms or long term clinical result; however, treatment with ELAPRASE has reduced spleen size similarly to patients 5 yrs and older.

It is not known if ELAPRASE is safe and effective in children under 16 months old.

RISK OF SERIOUS ALLERGIC REACTIONS

Risk of serious allergic reactions:
Some patients have experienced serious allergic reactions (including life-threatening anaphylactic reactions) during and up to 24 hours after treatment, regardless of how long they were taking ELAPRASE. Anaphylactic reactions are immediate and include breathing problems, low oxygen levels, low blood pressure, hives and/or swelling of the throat or tongue.

If a patient (you or your child) has experienced an anaphylactic reaction, the patient may require an extended period of observation by the patient’s healthcare team.

If you or your child has breathing problems, a fever, or a respiratory illness, you or your child may be at risk of life-threatening worsening of those conditions due to allergic reactions from ELAPRASE. Your healthcare team should be advised of those conditions before treatment with ELAPRASE because the information may affect the timing of ELAPRASE treatment.

You or your child should be closely watched during and after ELAPRASE treatment and you should confirm with your healthcare team in advance of treatment that it is prepared to manage serious allergic reactions, including anaphylactic reactions. Tell your healthcare team immediately if any signs of an allergic reaction happen. Those signs may include breathing problems, low blood pressure, rash, hives, itching, flushing, fever and/or headache.

When serious allergic reactions happened during clinical trials, later ELAPRASE treatments were managed with allergy-controlling drugs before or during treatment, a slower rate of ELAPRASE treatment, and/or early discontinuation of treatment.

Children with serious genetic mutations may be at risk for allergic reactions, serious side effects and antibody development. In a clinical study of children 7 years and younger, patients with certain types of genetic mutations experienced a higher number of allergic reactions, serious side effects, and development of an immune response to treatment. This immune response may interfere with the effectiveness of ELAPRASE. Talk to your healthcare team about whether you or your child may be at risk.

If you or your child has breathing problems, other respiratory illness, heart problems, or susceptibility to fluid overload, you or your child may be at higher risk of fluid overload during ELAPRASE treatment. Your healthcare team should be advised of those problems before treatment and you should confirm with your healthcare team in advance of treatment that it is appropriately trained to watch for signs of fluid overload and provide the necessary medical support. Patients at risk for fluid overload may require longer observation time.

What are possible side effects of ELAPRASE?
The most common side effects of ELAPRASE include:

  • In patients aged 5 and older:
    • Headache
    • Itching
    • Muscle and bone pain
    • Hives
    • Diarrhea
    • Cough
  • In patients aged 7 years or younger:
    • Fever
    • Rash
    • Vomiting
    • Hives

The most common side effects needing medical attention were allergic reactions, and included rash, hives, itching, flushing, fever, and headache. Tell your healthcare team immediately if any signs of an allergic reaction happen. These are not all the possible side effects of ELAPRASE.

For additional safety information, please click here for Full Prescribing Information, including Boxed Warning for Risk of Anaphylaxis, and discuss with your doctor

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

S44474 02/19

Elaprase

Questions about product support services? Contact OnePath: 1-866-888-0660

  • Home
  • About ELAPRASE
  • Access & Support
  • Stay Updated
  • Healthcare Provider Site
  • Site Map
  • Shire.com

© 2019 SHIRE ALL RIGHTS RESERVED

  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Use of Cookies
  • Unsubscribe

ELAPRASE and OnePath and the associated logos are registered trademarks of Shire or its affiliates. All other trademarks are the property of their respective owners. All content of this website including text, images, graphics, sound files, and their arrangement, belongs to Shire and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites. This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Terms of Use and online Privacy Policy for more information. While Shire makes reasonable efforts to include accurate, up-to-date information on the site, Shire makes no warranties or representations as to its accuracy. Shire assumes no liability for any errors or omissions in the content of the site.

ARE YOU A HEALTHCARE PROFESSIONAL?

The information in this section of elaprase.com is intended for U.S. healthcare professionals only.
Yes

You are about to leave this website.

Please be advised that Shire Pharmaceuticals has no control over the content or presentation of the site you are about to view. Shire's Privacy Policy does not apply to the website you are about to visit.
Continue Cancel

ELAPRASE (idursulfase) product updates and news

Sign up to stay updated.

Shire respects your personal information. All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our Privacy Policy Statement. We encourage you to read our Privacy Policy Statement by clicking on this link. This consent will be in effect until such a time as you opt out of the program.

Have Questions or Need Information About Product Services?

Contact OnePath® Support: 1-866-888-0660 Monday through Friday, 8:30 AM to 8:00 PM ET